Verastem keeps investors waiting in KRAS
The company now needs to carry out separate phase 2s of its G12D inhibitor VS-7375.
Ebvallo’s US soap opera plays on
The FDA apparently deems an uncontrolled study acceptable – five months after saying no.
Ideaya exits Werner and Pol theta
Ideaya discontinues IDE275 and IDE705, previously ditched by GSK.
FDA red and green lights: April 2026
Full US approval of Gilead’s Tecartus was the only positive decision last month.
An unexpected Serena knockback for Astra
A US advisory committee votes against camizestrant, but does endorse a new use for Truqap.
Roche sounds another warning over co-stimulation
The company drops the anti-CD19 x 4-1BB project englumafusp alfa.
